Last reviewed · How we verify
High Dose Psilocybin
At a glance
| Generic name | High Dose Psilocybin |
|---|---|
| Sponsor | Francisco A Moreno |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder (PHASE2)
- Psilocybin-assisted Treatment for Cannabis Use Disorder (PHASE1)
- Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease (EARLY_PHASE1)
- Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer (PHASE2)
- Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder (PHASE2)
- Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. (PHASE1)
- Subjective Experience Following Psilocybin (PHASE2)
- Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High Dose Psilocybin CI brief — competitive landscape report
- High Dose Psilocybin updates RSS · CI watch RSS
- Francisco A Moreno portfolio CI